Tanvex BioPharma, Inc. (TPE:6541)
Taiwan
· Delayed Price · Currency is TWD 56.50
-0.30 (-0.53%)
At close: Dec 5, 2025
Tanvex BioPharma Revenue
Tanvex BioPharma had revenue of 125.34M TWD in the quarter ending September 30, 2025, with 989.60% growth. This brings the company's revenue in the last twelve months to 224.83M, up 448.96% year-over-year. In the year 2024, Tanvex BioPharma had annual revenue of 34.68M, down -43.53%.
Revenue (ttm)
224.83M
Revenue Growth
+448.96%
P/S Ratio
66.55
Revenue / Employee
1.12M
Employees
200
Market Cap
14.96B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 34.68M | -26.73M | -43.53% |
| Dec 31, 2023 | 61.41M | 39.01M | 174.11% |
| Dec 31, 2022 | 22.40M | 17.00M | 314.43% |
| Dec 31, 2021 | 5.41M | 5.11M | 1,702.00% |
| Dec 31, 2020 | 300.00K | - | - |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Caliway Biopharmaceuticals | 34.99M |
| PharmaEssentia | 13.82B |
| Lotus Pharmaceutical | 18.66B |
| Bora Pharmaceuticals Co., LTD. | 21.10B |
| Oneness Biotech | 117.33M |
| Lumosa Therapeutics | 42.59M |
| Center Laboratories | 1.57B |
| Pegavision | 6.90B |